Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer

References

• Deschenes-Simard X, Kottakis F, Meloche S, et al. Erks in cancer: friends or foes? Cancer Res. 2014;74(2):412–419. doi: 10.1158/0008-5472.CAN-13-2381
   PubMed Web of Science ®Google Scholar
• Deng Q, Liao R, Wu BL, et al. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem. 2004;279(2):1050–1059. doi: 10.1074/jbc.M308644200
   PubMed Web of Science ®Google Scholar
• Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 2013;27(8):900–915. doi: 10.1101/gad.203984.112
   PubMed Web of Science ®Google Scholar
• Rahmouni S, Cerignoli F, Alonso A, et al. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol. 2006;8(5):524–531. doi: 10.1038/ncb1398
   PubMed Web of Science ®Google Scholar
• Zhu B, Ferry CH, Blazanin N, et al. PPARβ/δ promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling. Oncogene. 2014;33(46):5348–5359. doi: 10.1038/onc.2013.477
   PubMed Web of Science ®Google Scholar
• Chen JY, Hug C, Reyes J, et al. Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. Cell Rep. 2023;42(3):112252. doi: 10.1016/j.celrep.2023.112252
   PubMed Web of Science ®Google Scholar
• Lessard F, Igelmann S, Trahan C, et al. Senescence-associated ribosome biogenesis defects contributes to cell cycle arrest through the Rb pathway. Nat Cell Biol. 2018;20(7):789–799. doi: 10.1038/s41556-018-0127-y
   PubMed Web of Science ®Google Scholar
• Kong X, Kuilman T, Shahrabi A, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550(7675):270–274. doi: 10.1038/nature24037
   PubMed Web of Science ®Google Scholar
• Shin S, Buel GR, Wolgamott L, et al. ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate. Mol Cell. 2015;59(3):382–398. doi: 10.1016/j.molcel.2015.06.020
   PubMed Web of Science ®Google Scholar
• Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16 Ink4a and the p19 arf -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006;103(15):5947–5952. doi: 10.1073/pnas.0601273103
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437–450. doi: 10.1016/S1535-6108(03)00309-X
   PubMed Web of Science ®Google Scholar
• Caldwell ME, DeNicola GM, Martins CP, et al. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene. 2012;31(12):1599–1608. doi: 10.1038/onc.2011.350
   PubMed Web of Science ®Google Scholar
• Deschenes-Simard X, Parisotto M, Rowell MC, et al. Circumventing senescence is associated with stem cell properties and metformin sensitivity. Aging Cell. 2019;18(2):e12889. doi: 10.1111/acel.12889
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi: 10.1016/S0140-6736(16)00141-0
   PubMed Web of Science ®Google Scholar
• Morris J, Wang SC, Hebrok M, et al. Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683–695. doi: 10.1038/nrc2899
   PubMed Web of Science ®Google Scholar
• Collins MA, Yan W, Sebolt-Leopold JS, et al. MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology. 2014;146(3):822–34 e7. doi: 10.1053/j.gastro.2013.11.052
   PubMed Web of Science ®Google Scholar
• Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977–987. doi: 10.1097/01.pas.0000126675.59108.80
   PubMed Web of Science ®Google Scholar
• Sipos B, Frank S, Gress T, et al. Pancreatic intraepithelial neoplasia revisited and updated. IAP. 2009;9(1–2):45–54. doi: 10.1159/000178874
   Google Scholar
• Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011;71(14):5020–5029. doi: 10.1158/0008-5472.CAN-11-0908
   PubMed Web of Science ®Google Scholar
• Parisotto M, Vuong-Robillard N, Kalegari P, et al. The NAMPT inhibitor FK866 increases metformin sensitivity in pancreatic cancer cells. Cancers (Basel). 2022;14(22):5597. doi: 10.3390/cancers14225597
   PubMed Web of Science ®Google Scholar
• Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39(4):425–435. doi: 10.1097/MPA.0b013e3181c15963
   PubMed Web of Science ®Google Scholar
• Smirnov A, Cappello A, Lena AM, et al. ZNF185 is a p53 target gene following DNA damage. Aging. 2018;10(11):3308–3326. doi: 10.18632/aging.101639
   PubMedGoogle Scholar
• Lin CY, Navarro S, Reddy S, et al. CK2-mediated stimulation of pol I transcription by stabilization of UBF–SL1 interaction. Nucleic Acids Res. 2006;34(17):4752–4766. doi: 10.1093/nar/gkl581
   PubMed Web of Science ®Google Scholar
• Voit R, Grummt I. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc Natl Acad Sci U S A. 2001;98(24):13631–13636. doi: 10.1073/pnas.231071698
   PubMed Web of Science ®Google Scholar
• Perera Y, Farina HG, Gil J, et al. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity. Mol Cancer Ther. 2009;8(5):1189–1196. doi: 10.1158/1535-7163.MCT-08-1056
   PubMed Web of Science ®Google Scholar
• Ayrault O, Andrique L, Fauvin D, et al. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene. 2006;25(58):7577–7586. doi: 10.1038/sj.onc.1209743
   PubMed Web of Science ®Google Scholar
• Reynolds RC, Montgomery PO, Hughes B. Nucleolar “caps” produced by actinomycin D. Cancer Res. 1964;24:1269–1277.
   PubMed Web of Science ®Google Scholar
• van Sluis M, McStay B. A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage. Genes Dev. 2015;29(11):1151–1163. doi: 10.1101/gad.260703.115
   PubMed Web of Science ®Google Scholar
• Shav-Tal Y, Blechman J, Darzacq X, et al. Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. Mol Biol Cell. 2005;16(5):2395–2413. doi: 10.1091/mbc.e04-11-0992
   PubMed Web of Science ®Google Scholar
• Feric M, Vaidya N, Harmon TS, et al. Coexisting Liquid Phases Underlie Nucleolar Subcompartments. Cell. 2016;165(7):1686–1697. doi: 10.1016/j.cell.2016.04.047
   PubMed Web of Science ®Google Scholar
• Ide S, Imai R, Ochi H, et al. Transcriptional suppression of ribosomal DNA with phase separation. Sci Adv. 2020;6(42):6. doi: 10.1126/sciadv.abb5953
   Web of Science ®Google Scholar
• Kroschwald S, Maharana S, Mateju D, et al. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. Elife. 2015;4:e06807. doi: 10.7554/eLife.06807
   PubMed Web of Science ®Google Scholar
• Quin JE, Devlin JR, Cameron D, et al. Targeting the nucleolus for cancer intervention. Biochim Biophys Acta. 2014;1842(6):802–816. doi: 10.1016/j.bbadis.2013.12.009
   PubMed Web of Science ®Google Scholar
• Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18(1):51–63. doi: 10.1038/nrc.2017.104
   PubMed Web of Science ®Google Scholar
• Khot A, Brajanovski N, Cameron DP, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov. 2019;9(8):1036–1049. doi: 10.1158/2159-8290.CD-18-1455
   PubMed Web of Science ®Google Scholar
• Peltonen K, Colis L, Liu H, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014;25(1):77–90. doi: 10.1016/j.ccr.2013.12.009
   PubMed Web of Science ®Google Scholar
• Musso L, Mazzini S, Rossini A, et al. C-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical approach. Biochim Biophys Acta Gen Subj. 2018;1862(3):615–629. doi: 10.1016/j.bbagen.2017.12.002
   PubMed Web of Science ®Google Scholar
• Jacobs RQ, Huffines AK, Laiho M, et al. The small-molecule BMH-21 directly inhibits transcription elongation and DNA occupancy of RNA polymerase I in vivo and in vitro. J Biol Chem. 2022;298(1):101450. doi: 10.1016/j.jbc.2021.101450
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–2406. doi: 10.1056/NEJMoa1809775
   PubMed Web of Science ®Google Scholar
• Bruno PM, Liu Y, Park GY, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23(4):461–471. doi: 10.1038/nm.4291
   PubMed Web of Science ®Google Scholar
• Ozdian T, Holub D, Maceckova Z, et al. Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. J Proteomics. 2017;162:73–85. doi: 10.1016/j.jprot.2017.05.005
   PubMed Web of Science ®Google Scholar
• Sutton EC, DeRose VJ. Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin. J Biol Chem. 2021;296:100633. doi: 10.1016/j.jbc.2021.100633
   PubMed Web of Science ®Google Scholar
• Gadal O, Mariotte-Labarre S, Chedin S, et al. A34.5, a nonessential component of yeast RNA polymerase I, cooperates with subunit A14 and DNA topoisomerase I to produce a functional rRNA synthesis machine†. Mol Cell Biol. 1997;17(4):1787–1795. doi: 10.1128/MCB.17.4.1787
   PubMed Web of Science ®Google Scholar
• El Hage A, French SL, Beyer AL, et al. Loss of topoisomerase I leads to R-loop-mediated transcriptional blocks during ribosomal RNA synthesis. Genes Dev. 2010;24(14):1546–1558. doi: 10.1101/gad.573310
   PubMed Web of Science ®Google Scholar
• Silverstein RA, Gonzalez de Valdivia E, Visa N. The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6. Mol Cancer Res. 2011;9(3):332–340. doi: 10.1158/1541-7786.MCR-10-0084
   PubMed Web of Science ®Google Scholar
• Abraham KJ, Khosraviani N, Chan JNY, et al. Nucleolar RNA polymerase II drives ribosome biogenesis. Nature. 2020;585(7824):298–302. doi: 10.1038/s41586-020-2497-0
   PubMed Web of Science ®Google Scholar
• Loukopoulos P, Kanetaka K, Takamura M, et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29(3):193–203. doi: 10.1097/00006676-200410000-00004
   PubMed Web of Science ®Google Scholar
• Shojaee S, Caeser R, Buchner M, et al. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell. 2015;28(1):114–128. doi: 10.1016/j.ccell.2015.05.008
   PubMed Web of Science ®Google Scholar
• Unni AM, Harbourne B, Oh MH, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Elife. 2018;7: doi: 10.7554/eLife.33718
   PubMed Web of Science ®Google Scholar
• Leung GP, Feng T, Sigoillot FD, et al. Hyperactivation of MAPK signaling is deleterious to RAS/RAF-mutant melanoma. Mol Cancer Res. 2019;17(1):199–211. doi: 10.1158/1541-7786.MCR-18-0327
   PubMed Web of Science ®Google Scholar
• Wu PK, Hong SK, Park JI. Steady-state levels of phosphorylated mitogen-activated protein kinase kinase 1/2 determined by mortalin/HSPA9 and protein phosphatase 1 alpha in KRAS and BRAF tumor cells. Mol Cell Biol. 2017;37(18). doi: 10.1128/MCB.00061-17
   Web of Science ®Google Scholar
• Zafra MP, Parsons MJ, Kim J, et al. An in vivo kras allelic series reveals distinct phenotypes of common oncogenic variants. Cancer Discov. 2020;10(11):1654–1671. doi: 10.1158/2159-8290.CD-20-0442
   PubMed Web of Science ®Google Scholar
• Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553(7686):96–100. doi: 10.1038/nature25167
   PubMed Web of Science ®Google Scholar
• Kolodkin-Gal D, Roitman L, Ovadya Y, et al. Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions. Gut. 2022;71(2):345–355. doi: 10.1136/gutjnl-2020-321112
   PubMed Web of Science ®Google Scholar
• Haugstetter AM, Loddenkemper C, Lenze D, et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer. 2010;103(4):505–509. doi: 10.1038/sj.bjc.6605784
   PubMed Web of Science ®Google Scholar
• Igelmann S, Lessard F, Uchenunu O, et al. A hydride transfer complex reprograms NAD metabolism and bypasses senescence. Mol Cell. 2021;81(18):3848–65 e19. doi: 10.1016/j.molcel.2021.08.028
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi: 10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar